NCT03226275View on ClinicalTrials.gov

Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 9, 2017

Primary Completion Date

September 9, 2017

Study Completion Date

September 9, 2017

Conditions
Healthy
Interventions
DRUG

Bisoprolol-Amlodipine FDC

Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) either on Day 1 or Day 15 under fasting or fed conditions.

DRUG

Bisoprolol

Participants received 5 mg bisoprolol tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.

DRUG

Amlodipine

Participants received 5 mg amlodipine tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.

Trial Locations (1)

100053

Xuanwu Hospital, Beijing

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03226275 - Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants | Biotech Hunter | Biotech Hunter